

Supplementary Table 4. Comparison of characteristics on admission between non-survivors and survivors in HBV-ACLF patients with cirrhosis of the derivation cohort

Variable	Total (n=172)	Non-survivor (n=41)	Survivor (n=131)	Univariate Cox regression		Multivariate Cox regression	
				HR (95% CI)	P-value	HR (95% CI)	P-value
Age (years)	49.87±11.77	51.81±12.15	49.25±11.63	1.015 (0.989–1.042)	0.266		
Gender, female/male	40/132	11/30	29/102	0.814 (0.408–1.625)	0.560		
Fatigue	8 (4.7)	1 (2.4)	7 (5.3)	0.501 (0.069–3.648)	0.495		
Alcohol consumption	13 (7.6)	3 (7.3)	10 (7.7)	0.912 (0.473–1.757)	0.783		
HBV reactivation	96 (55.8)	25 (61.0)	71 (54.2)	1.262 (0.674–2.364)	0.467		
Drug use	22 (12.8)	3 (7.3)	19 (14.5)	0.493 (0.152–1.598)	0.239		
Bacterial infection	82 (47.7)	26 (63.4)	56 (42.7)	1.988 (1.053–3.753)	0.034		
UGIB	27 (15.7)	6 (14.6)	21 (16.0)	1.098 (0.462–2.611)	0.832		
Ascites, mild/serve	73/47	17/15	56/32	1.395 (0.926–2.103)	0.111		
HE, mild/serve	15/8	7/8	8/0	4.893 (3.146–7.609)	<0.001	2.856 (1.656–4.925)	<0.001
CRP (mg/L)	10.80 (7.27–17.13)	11.60 (7.60–17.30)	10.40 (7.10–16.80)	1.008 (0.987–1.029)	0.484		
WBC ($\times 10^9/L$)	6.10 (4.80–8.60)	7.70 (5.45–9.50)	5.90 (4.50–7.90)	1.079 (1.000–1.164)	0.049		
Neutrophil ($\times 10^9/L$)	4.20 (3.10–6.10)	5.80 (3.65–7.30)	3.90 (3.00–5.70)	1.092 (1.004–1.188)	0.040		
RBC ($\times 10^{12}/L$)	3.89±0.73	4.01±0.83	3.85±0.70	1.268 (0.826–1.945)	0.277		
Platelet ($\times 10^9/L$)	100.03±49.30	98.00±45.58	100.66±50.56	0.999 (0.993–1.005)	0.707		
Total protein (g/L)	59.16±8.93	58.16±5.74	59.48±9.71	0.985 (0.950–1.020)	0.392		
Albumin (g/L)	30.80±4.60	30.87±3.80	30.78±4.83	0.994 (0.930–1.078)	0.804		
ALT (U/L)	183.50 (73.25–427.00)	275.00 (127.00–546.00)	153.00 (66.00–416.00)	1.001 (1.000–1.001)	0.121		
AST (U/L)	158.00 (84.00–309.75)	249.00 (144.00–404.50)	143.00 (78.00–266.00)	1.001 (1.000–1.002)	0.003	1.002 (1.000–1.003)	0.004
Serum bilirubin (mg/dL)	18.13 (11.52–23.74)	21.29 (16.43–25.58)	17.08 (10.41–23.57)	1.058 (1.018–1.100)	0.004	1.059 (1.011–1.111)	0.017
Creatinine (mg/dL)	0.72 (0.62–0.83)	0.74 (0.62–0.94)	0.71 (0.62–0.94)	3.303 (1.343–8.122)	0.009	6.174 (2.461–15.491)	<0.001
Potassium (mmol/L)	4.17±0.59	4.21±0.50	4.16±0.61	1.124 (0.685–1.845)	0.643		
Sodium (mmol/L)	136.92±4.48	137.93±4.29	136.60±4.51	1.075 (0.988–1.170)	0.091		
PT-INR	2.00 (1.72–2.49)	2.70 (2.19–3.63)	1.88 (1.67–2.23)	2.084 (1.734–2.505)	<0.001	1.825 (1.416–2.352)	<0.001
Log ₁₀ (DNA)	4.61 (3.36–6.20)	5.49 (4.05–7.24)	4.48 (3.01–5.85)	1.233 (1.051–1.447)	0.010	1.238 (1.051–1.458)	0.010
Log ₁₀ (HBsAg)	2.96 (1.94–3.48)	2.98 (1.78–3.61)	2.96 (1.98–3.46)	1.008 (0.794–1.281)	0.945		
VDBP ($\mu g/mL$)	47.43 (31.71–63.77)	29.26 (23.93–44.78)	53.41 (39.06–67.45)	0.951 (0.931–0.970)	<0.001	0.977 (0.955–0.999)	0.038

Values are presented as mean±standard deviation, number (range), or number (%) unless otherwise indicated.

HBV-ACLF, hepatitis B virus-related acute-on-chronic liver failure; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; UGIB, upper gastrointestinal bleeding; HE, hepatic encephalopathy; CRP, C-reactive protein; WBC, white blood cell; RBC, red blood cell; ALT, alanine aminotransferase; AST, aspartate amino transferase; PT-INR, prothrombin time-international normalized ratio; VDBP, vitamin D-binding protein.